Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial

BACKGROUND: Natalizumab (NTZ) discontinuation leads to multiple sclerosis reactivation. The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those who were switched to subcutaneous interferon 1b (IFNB) treatment. METHODS: 1-year randomized, rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gobbi, Claudio, Meier, Dominik S, Cotton, François, Sintzel, Martina, Leppert, David, Guttmann, Charles R G, Zecca, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750382/
https://www.ncbi.nlm.nih.gov/pubmed/23915113
http://dx.doi.org/10.1186/1471-2377-13-101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750382/
https://www.ncbi.nlm.nih.gov/pubmed/23915113
http://dx.doi.org/10.1186/1471-2377-13-101

Ejemplares similares